PriceTargets.com logo

OKYO Pharma - OKYO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 414.33%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.36 As of 07/26/2024 01:00 AM ET
▲ +0.01 (0.74%)

This chart shows the closing price for OKYO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OKYO Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OKYO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OKYO

Analyst Price Target is $7.00
▲ +414.33% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for OKYO Pharma in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 414.33% upside from the last price of $1.36.

This chart shows the closing price for OKYO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in OKYO Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00Low
3/22/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $7.00Low
1/8/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $5.00Low
12/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$4.00Low
11/2/2023HC WainwrightInitiated CoverageBuy$4.00Low
(Data available from 7/26/2019 forward)

News Sentiment Rating

0.50 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/28/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
OKYO Pharma logo
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $1.36
Low: $1.35
High: $1.47

50 Day Range

MA: $1.37
Low: $1.13
High: $1.68

52 Week Range

Now: $1.36
Low: $1.09
High: $3.07

Volume

28,641 shs

Average Volume

95,511 shs

Market Capitalization

$39.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OKYO Pharma?

The following Wall Street analysts have issued reports on OKYO Pharma in the last twelve months: HC Wainwright.
View the latest analyst ratings for OKYO.

What is the current price target for OKYO Pharma?

1 Wall Street analysts have set twelve-month price targets for OKYO Pharma in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 414.3%. HC Wainwright has the highest price target set, predicting OKYO will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for OKYO Pharma in the next year.
View the latest price targets for OKYO.

What is the current consensus analyst rating for OKYO Pharma?

OKYO Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OKYO will outperform the market and that investors should add to their positions of OKYO Pharma.
View the latest ratings for OKYO.

What other companies compete with OKYO Pharma?

Other companies that are similar to OKYO Pharma include Innate Pharma, Fennec Pharmaceuticals, Metagenomi, INmune Bio and Cardiol Therapeutics. Learn More about companies similar to OKYO Pharma.

How do I contact OKYO Pharma's investor relations team?

The company's listed phone number is 44-20-7495-2379. The official website for OKYO Pharma is www.okyopharma.com. Learn More about contacing OKYO Pharma investor relations.